Flooid Announces Strategic Partnership with FreedomPay to Expand Global Reach

The partnership will bring enhanced commerce functionality to Retailers around the world.

London, England, Jan. 13, 2023 (GLOBE NEWSWIRE) — Flooid today announces a strategic partnership with FreedomPay, the global leader in Next Level Commerce™, to bring industry-leading Retail solutions to merchants globally.

Powered by FreedomPay, Flooid allows merchants to connect their retail channels, removing barriers between online and in-store payments. FreedomPay’s data-driven commerce platform grants merchants access to valuable analytics and Business Intelligence platform to drive further customer engagement and loyalty through targeted offers and incentives, all within a frictionless integrated payment solution.

“Through this partnership with FreedomPay, we are bringing enhanced innovation, choice, and flexibility to retailers on the Flooid platform,” said Donna Stevens, Senior VP of Product and Marketing at Flooid. Our goal is to empower merchants with the tools they need to provide the best shopping experience to consumers globally.”

The FreedomPay platform enables enterprises to provide a consistent payment experience for their customers globally, creating a seamless and flexible retail experience managing security, data and loyalty all from a single, unified tech stack.

“The partnership between FreedomPay and Flooid will bring a world-class commerce experience to retailers and shoppers around the globe,” said Liesl Smith, Senior VP of Marketing and Sales Enablement at FreedomPay. “Together we are committed to delivering a seamless payment experience to customers, enabling an innovative and seamless omnichannel payment environment.”

About FreedomPay

FreedomPay’s Next Level Commerce™ platform transforms existing payment systems and processes from legacy to leading edge. As the premier choice for many of the largest companies across the globe in retail, hospitality, lodging, gaming, sports and entertainment, foodservice, education, healthcare and financial services, FreedomPay’s technology has been purposely built to deliver rock solid performance in the highly complex environment of global commerce. The company maintains a world-class security environment and was first to earn the coveted validation by the PCI Security Standards Council against Point-to-Point Encryption (P2PE/EMV) standard in North America. FreedomPay’s robust solutions across payments, security, identity, and data analytics are available in-store, online and on-mobile and are supported by rapid API adoption. The award winning FreedomPay Commerce Platform operates on a single, unified technology stack across multiple continents allowing enterprises to deliver an innovative Next Level experience on a global scale. www.freedompay.com

About Flooid

Flooid helps retailers create the seamless shopping experiences customers demand. Flooid’s unified commerce platform empowers merchants to sell to customers flexibly and consistently wherever they are and however they choose to shop. Our best of breed open ecosystem givers retailers the power to connect leading retail tech partners with a single unified commerce platform to engage with your shoppers, sell more effectively across channels and adapt to retail shopping changes we have yet to imagine.

Jennifer Tayebi
Hill+Knowlton Strategies for FreedomPay
+1 734 395 0780
Jennifer.Tayebi@hkstrategies.com

GlobeNewswire Distribution ID 8729158

Hisense élargit les options de divertissement à domicile pour les consommateurs sud-africains avec le lancement du nouveau téléviseur ULED 8K U80H Mini-LED

CAPE TOWN, Afrique du Sud, 13 janvier 2023 /PRNewswire/ — Hisense, marque d’électronique mondiale leader, a récemment annoncé la sortie du téléviseur ULED 8K U80H Mini-LED en Afrique du Sud. Le téléviseur U80H offre une profondeur et des détails inégalés, avec 33 millions de pixels, soit 4 fois plus qu’un téléviseur 4K standard. Ce téléviseur intelligent de nouvelle génération est également doté d’un certain nombre de fonctionnalités innovantes, qui créent une expérience de divertissement véritablement immersive.

Le téléviseur U80H est équipé d’un upscaler d’image par IA 8K, capable d’augmenter les performances de l’image pour obtenir des normes d’image d’une qualité exceptionnelle avec des détails très précis. Au lieu de simplement dupliquer les pixels, l’algorithme intelligent peut analyser les images et restituer les bons pixels pour améliorer la qualité et la précision de l’image. En outre, le processeur Hisense Hi-View Engine Pro intègre un ensemble d’algorithmes de deep learning pour analyser intelligemment les images trame par trame et ajuster les pixels avec précision, en optimisant les ombres et la luminosité. La combinaison de ces outils innovants permet d’obtenir un affichage à plage dynamique élevée, avec une riche gamme de couleurs, haute définition et avec une haute fluidité de mouvement.

Le téléviseur U80H utilise la technologie Mini-LED Pro de Hisense qui optimise plus de 500 zones de gradation locales pour apporter des améliorations notables à la plage de luminosité, à la visibilité des détails et à la netteté entre les images claires et sombres. Grâce aux cristaux Quantum Dot Colour, les trois couleurs primaires sont affichées avec beaucoup plus de précision que sur les téléviseurs LED classiques, et la technologie de pointe HDR10+ utilise les métadonnées dynamiques de chaque image pour ajuster les paramètres de couleur, de luminosité et de contraste, ce qui donne une image beaucoup plus réaliste. Pour le son, bien que le téléviseur U80H puisse être connecté à n’importe quelle enceinte, il est également doté de la technologie Dolby Atmos® de classe mondiale pour une expérience audio des plus riches.

Android TV est intégré directement au téléviseur U80H, ce qui signifie que les utilisateurs peuvent choisir parmi plus de 400 000 films et émissions grâce aux services de streaming. Le produit se revendique comme « la seule façon de profiter chez soi d’une image, d’un son et d’une échelle dignes de l’IMAX », grâce à la technologie IMAX® Enhanced qui associe des contenus HDR 4K remastérisés numériquement et des technologies audio DTS® aux meilleurs produits électroniques grand public et plateformes de streaming. En ce qui concerne les modes de divertissement, les appareils prennent en charge la technologie Game Mode PRO avec eARC, ALLM et VRR pour minimiser le décalage des entrées, la gigue de l’écran et les tremblements.

Pour une utilisation facile, ces modes et d’autres fonctions peuvent être contrôlés à l’aide de la commande vocale, ce qui permet aux utilisateurs de n’utiliser que leur voix pour rechercher, régler et contrôler les téléviseurs et autres appareils intelligents de la maison.

Le modèle Hisense U80H 75 pouces est disponible chez Hirsch’s. Veuillez consulter https://hisense.co.za/products/hisense-u80h-mini-led-uled-8k-tv/.

Photo – https://mma.prnewswire.com/media/1982077/image_5020023_14499256.jpg

Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines

Sabin Vaccine Institute Awarded BARDA Contract With Funding Potential up to $214M for Ebola Sudan and Marburg Vaccines

The Sabin Vaccine Institute will produce up to 100,000 doses of Sabin’s Ebola Sudan vaccine as part of a new, multi-year contract with BARDA

WASHINGTON, Jan. 12, 2023 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Sabin a multi-year contract with funding potential for up to $214 million to advance the development and production of single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.

There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infected.

BARDA, part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR), will initially invest approximately $35 million to produce up to 100,000 doses of Sabin’s Ebola Sudan virus (ChAd3-SUDV) vaccine. These vaccines may be used as part of ongoing U.S. preparedness efforts and in response to future global outbreaks.

The Sabin vaccine was the first to arrive in Uganda during the recent Ebola Sudan virus outbreak that caused 55 deaths after the World Health Organization included it as one of three vaccines for possible use in an outbreak trial in Uganda. The country declared the Ebola Sudan outbreak had ended on January 11, four months after the first confirmed case.

“Sabin successfully delivered Ebola Sudan vaccine doses to Uganda within 79 days of the start of the outbreak – quite an impressive accomplishment,” says Sabin Chief Executive Officer Amy Finan. “This new contract enables Sabin to produce up to 100,000 doses so the world is prepared in advance for future outbreaks.”

In addition to participating in recent outbreak activities, Sabin continues its Sudan development plan and has initiated Phase 2 clinical trial planning in Uganda and Kenya. Based on previous clinical trials, Sabin’s Ebola Sudan vaccine is safe and immunogenic, and in nonhuman primate studies has demonstrated rapid protection, durability up to 12 months, and efficacy.

In addition to Sabin’s ChAd3-SUDV vaccine, the contract also includes support to manufacture Sabin’s vaccine against Marburg virus (ChAd3-MARV), which would generate doses that could also be used in trials and in response to a possible Marburg virus outbreak. As recently as last July, two people in Ghana died after being infected with Marburg virus, reinforcing the urgent need for a vaccine.

The new contract leverages a partnership with BARDA that began in 2019, when the agency awarded Sabin another multi-year contract valued at $128 million to further the development of vaccines against both the Marburg and Ebola Sudan viruses.

“BARDA has been a supportive partner as we take these essential steps in pandemic preparedness,” said Finan. “The Ebola Sudan outbreak in Uganda underscored the critical need for readily available solutions. We’ll now have ample material to respond quickly to such an outbreak in the future.”

This project will be funded in whole with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50123C00010.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

About Ebola Sudan and Marburg

Ebola Sudan and Marburg are members of the filovirus family. Both can cause severe hemorrhagic fever in humans and nonhuman primates. No therapeutic treatment of these hemorrhagic fevers has been licensed to date. Marburg and Ebola viruses are transmitted to humans by infected animals, particularly fruit bats. Once a human is infected, the virus can spread to others through close personal contact or contact with bodily fluids. Isolation of infected people is currently the centerpiece of filovirus control.

Marburg was the first filovirus to be recognized in 1967 when outbreaks of hemorrhagic fever were reported in a few Europe-based laboratories including in the town of Marburg, Germany. Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and in southern Sudan. The outbreaks involved what eventually proved to be two different species of Ebola virus; both were named after the nations in which they were discovered.

For media inquiries:

press@sabin.org

Media Contact:
Monika Guttman
Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 662-1841
press@sabin.org

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/539c9127-e5d6-4b32-9e89-780f7461314b

GlobeNewswire Distribution ID 8728283

Sabin Vaccine Institute recebe US $ 35 milhões da BARDA com potencial de até US $ 214 milhões para a fabricação de vacinas Ebola Sudão e Marburg

Sabin Vaccine Institute fecha contrato com a BARDA com potencial de financiamento de até US $ 214 milhões para fabricação de vacinas contra Ebola Sudão e Marburg

O Sabin Vaccine Institute irá produzir até 100.000 doses da vacina Sabin Ebola Sudão como parte de um novo contrato plurianual com a BARDA

WASHINGTON, Jan. 12, 2023 (GLOBE NEWSWIRE) — O Sabin Vaccine Institute anunciou hoje que a Biomedical Advanced Research and Development Authority (BARDA) fechou com a Sabin um contrato plurianual com potencial de financiamento de até US $ 214 milhões para o avanço do desenvolvimento e da produção de vacinas candidatas à dose única para as doenças causadas pelos vírus Ebola Sudão e Marburg.

Atualmente não existem vacinas licenciadas contra os vírus Ebola Sudão e Marburg, que causam febre hemorrágica e matam aproximadamente metade das pessoas infectadas.

A BARDA, parte da Administração de Preparação e Resposta Estratégica (ASPR) do Departamento de Saúde e Serviços Humanos dos EUA, investirá inicialmente aproximadamente US $ 35 milhões para produzir até 100.000 doses da vacina da Sabin contra o vírus Ebola Sudão (ChAd3-SUDV). Essas vacinas podem ser usadas como parte dos esforços contínuos de preparação dos EUA e em resposta a futuros surtos globais.

A vacina Sabin foi a primeira a chegar a Uganda durante o recente surto do vírus Ebola no Sudão que causou 55 mortes, depois que a Organização Mundial de Saúde a incluiu como uma das três vacinas para possível uso em um teste de surto em Uganda. O país declarou que o surto de Ebola no Sudão havia terminado em 11 de janeiro, quatro meses após o primeiro caso confirmado.

“A Sabin entregou com sucesso a Uganda doses da vacina contra o Ebola Sudão em 79 dias depois do início do surto – uma conquista impressionante”, disse a Diretora Executiva da Sabin, Amy Finan. “Este novo contrato permite que a Sabin produza até 100.000 doses para que o mundo esteja preparado com antecedência para futuros surtos.”

Além de participar de atividades recentes de surto, a Sabin continua seu plano de desenvolvimento no Sudão e iniciou a Fase 2 de planejamento de ensaios clínicos em Uganda e no Quênia. Com base em ensaios clínicos anteriores, a vacina contra o Ebola Sudão da Sabin é segura e imunogênica, e em estudos com primatas não humanos demonstrou proteção rápida, durabilidade de até 12 meses e eficácia.

Além da vacina ChAd3-SUDV da Sabin, o contrato também inclui suporte para a fabricação da vacina da Sabin contra o vírus Marburg (ChAd3-MARV), que podem gerar doses que podem ser usadas em testes e em resposta a um possível surto do vírus Marburg. Em Julho passado, duas pessoas em Gana morreram depois de terem sido infectadas com o vírus Marburg, e isso demonstra claramente a necessidade urgente da criação de vacinas.

O novo contrato alavanca uma parceria com a BARDA que teve início em 2019, quando a agência fechou com a Sabin outro contrato de vários anos com um valor de US $ 128 milhões para o desenvolvimento de vacinas contra os vírus Marburg e Ebola Sudão.

“A BARDA tem sido parceira de apoio às nossas medidas essenciais para a preparação para a pandemia”, disse Finan. “O surto de Ebola Sudão em Uganda ressaltou a necessidade vital de soluções prontamente disponíveis. E teremos amplo material para responder rapidamente a esse surto no futuro.”

Este projeto será financiado, no todo, com fundos federais do Departamento de Saúde e Serviços Humanos; Administração para Preparação e Resposta Estratégica; Autoridade de Pesquisa e Desenvolvimento Avançado Biomédico, sob o contrato número 75A50123C00010.

Sobre o Sabin Vaccine Institute

O Sabin Vaccine Institute é um dos principais defensores da expansão do acesso e uso de vacinas em todo o mundo, do avanço da pesquisa e desenvolvimento de vacinas e da ampliação do conhecimento e inovação das vacinas. Revelando o potencial das vacinas através da parceria, o Sabin criou um ecossistema robusto de financiadores, inovadores, implementadores, profissionais, formuladores de políticas e partes interessadas públicas para avançar sua visão de um futuro livre de doenças evitáveis. Como uma organização sem fins lucrativos com três décadas de experiência, o Sabin está empenhado em encontrar soluções duradouras que levem todos os benefícios das vacinas a todas as pessoas, independentemente de quem sejam ou de onde vivem. No Sabin, acreditamos no poder das vacinas para mudar o mundo. Para mais informação, visite www.sabin.org e siga-nos no Twitter, @SabinVaccine.

Sobre a Ebola Sudão e Marburg

Ebola Sudão e Marburg são membros da família dos filovírus. Ambos podem causar febre hemorrágica grave em seres humanos e primatas não humanos. Nenhum tratamento terapêutico das febres hemorrágicas foi licenciado até o momento. Os vírus Marburg e Ebola são transmitidos aos seres humanos por animais infectados, particularmente pelos morcegos-fruta. Uma vez infectada, uma pessoa pode transmitir o vírus para outras pessoas através do contato pessoal próximo ou com fluidos corporais. O isolamento das pessoas infectadas atualmente é a parte central do controle do filovírus.

O Marburg foi o primeiro filovírus a ser identificado em 1967, quando surtos de febre hemorrágica foram relatados em alguns laboratórios da Europa, incluindo na cidade de Marburg, Alemanha. A ebola foi identificada em 1976, quando dois surtos simultâneos ocorreram no norte do Zaire (agora RDC) em uma aldeia perto do rio Ebola e sul do Sudão. Os surtos envolveram o que eventualmente provou ser duas espécies diferentes do vírus Ebola; ambos receberam o nome nações em que foram descobertos.

Para Informações para a Mídia:

press@sabin.org

Contato com a Mídia:
Monika Guttman
Especialista em Relações com a Mídia
Sabin Vaccine Institute
+1 (202) 662-1841
press@sabin.org

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/539c9127-e5d6-4b32-9e89-780f7461314b/pt

GlobeNewswire Distribution ID 8729001

Le Sabin Vaccine Institute reçoit 35 millions de dollars de la BARDA avec un potentiel pouvant atteindre jusqu’à 214 millions de dollars pour les vaccins Ebola-Soudan et Marburg

Le Sabin Vaccine Institute remporte un contrat avec la BARDA dont le potentiel de financement pourrait atteindre 214 millions de dollars pour les vaccins contre les virus Ebola-Soudan et Marburg

Le Sabin Vaccine Institute produira jusqu’à 100 000 doses de vaccin de Sabin contre le virus Ebola-Soudan dans le cadre d’un nouveau contrat pluriannuel avec la BARDA

WASHINGTON, 12 janv. 2023 (GLOBE NEWSWIRE) — Le Sabin Vaccine Institute a annoncé aujourd’hui que la Biomedical Advanced Research and Development Authority (BARDA) avait attribué à Sabin un contrat pluriannuel avec un potentiel de financement pouvant atteindre 214 millions de dollars pour faire progresser le développement et la production de candidats vaccins à dose unique pour les maladies que causent les virus Ebola-Soudan et Marburg.

Il n’existe actuellement aucun vaccin autorisé contre les virus Ebola-Soudan et Marburg, qui causent des fièvres hémorragiques et tuent à peu près la moitié des personnes infectées.

La BARDA, qui fait partie de l’Administration pour la préparation et la réponse stratégiques (Administration for Strategic Preparedness and Response, ASPR) du Département de la Santé et des Services sociaux des États-Unis, investira au départ environ 35 millions de dollars pour produire jusqu’à 100 000 doses de vaccin de Sabin contre le virus Ebola-Soudan (ChAd3-SUDV). Ces vaccins pourront être utilisés dans le cadre des efforts actuels de préparation des États-Unis et en réponse aux futures épidémies mondiales.

Le vaccin de Sabin a été le premier à arriver en Ouganda lors de la récente épidémie de virus Ebola-Soudan qui a tué 55 personnes après que l’Organisation mondiale de la Santé l’a inclus comme l’un des trois vaccins pouvant être utilisés dans un essai contre les cas d’épidémie en Ouganda. Le pays a déclaré que l’épidémie d’Ebola-Soudan s’était terminée le 11 janvier, quatre mois après le premier cas confirmé.

« Sabin est parvenue à fournir des doses de vaccin contre l’Ebola-Soudan en Ouganda dans les 79 jours qui ont suivi le début de l’épidémie, ce qui est réellement impressionnant », a commenté Amy Finan, présidente-directrice générale de Sabin. « Ce nouveau contrat permet à Sabin de produire jusqu’à 100 000 doses afin que le monde soit préparé à l’avance aux futures épidémies. »

En plus de participer aux récentes activités contre les épidémies, Sabin poursuit son plan de développement au Soudan et a initié la planification d’un essai clinique de phase 2 en Ouganda et au Kenya. Sur la base des précédents essais cliniques, le vaccin de Sabin contre l’Ebola-Soudan est sûr et immunogène, et lors d’études sur des primates non humains, il a démontré son efficacité, sa protection à action rapide et sa durabilité jusqu’à 12 mois.

Outre le vaccin ChAd3-SUDV de Sabin, le contrat comprend aussi un soutien à la fabrication du vaccin de Sabin contre le virus Marburg (ChAd3-MARV), consistant en la production de doses pouvant également être utilisées dans des essais et en réponse à une possible épidémie de virus Marburg. Pas plus tard qu’en juillet de cette année, deux personnes sont mortes au Ghana après avoir été infectées par le virus Marburg, renforçant ainsi le besoin urgent d’un vaccin.

Le nouveau contrat s’appuie sur un partenariat avec la BARDA qui a débuté en 2019, lorsque l’agence a attribué à Sabin un autre contrat pluriannuel d’une valeur de 128 millions de dollars pour poursuivre le développement de vaccins contre les virus Marburg et Ebola-Soudan.

« L’aide que nous apporte la BARDA en tant que partenaire est inestimable alors que nous prenons ces mesures essentielles pour nous préparer aux pandémies », a ajouté Mme Finan. « L’épidémie d’Ebola-Soudan en Ouganda a souligné qu’il était réellement crucial de disposer de solutions prêtes à l’emploi. Nous possèderons désormais des ressources suffisantes pour réagir rapidement à une telle épidémie à l’avenir. »

Ce projet sera financé en totalité par des fonds fédéraux du Département de la Santé et des Services sociaux, l’Administration pour la préparation et la réponse stratégiques et la Biomedical Advanced Research and Development Authority, sous le contrat numéro 75A50123C00010.

À propos du Sabin Vaccine Institute

Le Sabin Vaccine Institute est l’un des principaux défenseurs de l’élargissement de l’accès aux vaccins et de leur adoption à l’échelle mondiale, de l’avancement de la recherche et du développement de vaccins et de l’amplification des connaissances et de l’innovation en matière de vaccins. Libérant le potentiel des vaccins par le partenariat, Sabin a bâti un écosystème robuste de bailleurs de fonds, innovateurs, agents de mise en œuvre, praticiens, décideurs politiques et parties prenantes publiques pour faire avancer sa vision d’un avenir où les maladies évitables ont enfin disparu. En tant qu’organisation sans but lucratif comptant trois décennies d’expérience, Sabin s’est engagée à trouver des solutions qui durent et à étendre tous les bienfaits des vaccins à l’ensemble des individus, peu importe qui ils sont et où ils résident. Chez Sabin, nous sommes convaincus que les vaccins ont le pouvoir de changer le monde. Pour de plus amples informations, rendez-vous sur le site www.sabin.org et suivez-nous sur Twitter, @SabinVaccine.

À propos des virus Ebola-Soudan et Marburg

Ebola-Soudan et Marburg font partie de la famille des filovirus. Les deux peuvent causer des fièvres hémorragiques sévères chez l’humain et les primates non humains. Aucun traitement thérapeutique de ces fièvres hémorragiques n’a été autorisé à ce jour. Les virus Marburg et Ebola sont transmis aux humains par des animaux infectés, en particulier les chauves-souris frugivores. Une fois qu’un être humain est infecté, ces virus peuvent se propager à d’autres par le biais d’un contact personnel étroit ou d’un contact avec des fluides corporels. L’isolation des personnes infectées constitue actuellement la principale stratégie pour contrôler les filovirus.

Marburg a été le premier filovirus à être reconnu en 1967 lorsque des épidémies de fièvre hémorragique ont été signalées dans plusieurs laboratoires basés en Europe, y compris dans la ville de Marbourg, en Allemagne. Le virus Ebola a été identifié en 1976 lorsque deux épidémies se sont produites simultanément dans le nord du Zaïre (devenu la RDC), dans un village près de la rivière Ebola et dans le sud du Soudan. Ces épidémies ont impliqué ce qui s’est finalement avéré être deux espèces différentes de virus Ebola ; chacune devant son nom à la nation dans laquelle elle a été découverte.

Pour toute demande des médias :

press@sabin.org

Contact auprès des médias :
Monika Guttman
Spécialiste des relations avec les médias
Sabin Vaccine Institute
+1 (202) 662-1841
press@sabin.org

Une photo accompagnant ce communiqué de presse est disponible à l’adresse https://www.globenewswire.com/NewsRoom/AttachmentNg/539c9127-e5d6-4b32-9e89-780f7461314b/fr

GlobeNewswire Distribution ID 8729001

German, French Ministers Call for African Permanent Seats on UNSC

ADDIS ABABA, ETHIOPIA — The foreign ministers of France and Germany have voiced support for Africa to receive two permanent seats on the powerful U.N. Security Council.

German Foreign Minister Annalena Baerbock said she and French Foreign Minister Catherine Colonna added their support to an African push for permanent seats on the Security Council.

Baerbock spoke after she and Colonna met with African Union Chairperson Moussa Faki at AU headquarters in Addis Ababa.

“As European partners and I, as a German foreign minister, we see that the world in 2023 is not the same than that after World War Two, and therefore we are supporting two permanent seats for the African continent,” Baerbock said.

African leaders have for years called for a permanent seat on the powerful U.N. body.

Outgoing African Union Chairman Macky Sall, also the president of Senegal, reiterated that demand at the September U.N. General Assembly.

He said Africa should also have a seat in the G-20 group of the world’s largest economies.

U.S. President Joe Biden backed both efforts at the U.S.-Africa Leaders Summit in Washington last month.

Currently, the Security Council has five permanent members — Britain, China, France, Russia, and the United States. Other countries are elected to the Council for two-year terms by the U.N. General Assembly.

Having permanent seats on the Security Council would for the first time give African countries veto power over U.N. resolutions.

Meanwhile, Baerbock said Russia’s invasion of Ukraine underscored the importance of relations between the European Union and the African Union.

“As Russia is attacking the European peace order this needs more support from our friends,” Baerbock said. “We need you and we need Africa in defending our European peace order.”

Baerbock on Thursday made a visit to a World Food Program warehouse storing donated Ukrainian grain and condemned Moscow for using food as a weapon of war.

She was referring to Russian forces blocking some Ukrainian grain exports as the Horn of Africa suffers through a record drought that has tens of millions struggling with hunger.

The two foreign ministers also met with Ethiopia’s Prime Minister Abiy Ahmed on Thursday and called for accountability for atrocities committed during the war in the northern Tigray region.

Rights groups accuse all sides of committing rapes, torture, and extra-judicial killings during the two-year war.

The EU suspended some support for Ethiopia over the abuses and says accountability in the war is a condition for normalizing relations.

French Foreign Minister Colonna’s visit will include a grant of about 30 million U.S. dollars to aid people affected by the war.

The foreign ministers are in Addis to support a November peace deal between Ethiopia’s federal government and Tigray authorities.

Since the agreement, Ethiopia has restored the flow of humanitarian aid and some basic services to Tigray, while Eritrea has withdrawn its forces from parts of the region.

On Tuesday, the Tigray People’s Liberation Front began turning over heavy weapons to the Ethiopian army.

Source: Voice of America

Tracking Malaria Trends and Progress Amidst a Host of Challenges

Last month, the World Health Organization (WHO) released its 2022 World Malaria Report (WMR), an annual report that provides a comprehensive update on global and regional malaria data and trends. The following paragraphs share a few of the report’s main highlights, and also briefly recap Eritrea’s own national progress and efforts toward prevention and control (based on both local sources and the WMR).

General background

Malaria is a severe, life-threatening disease caused by Plasmodium parasites, which are spread to people through the bites of infected female Anopheles mosquitoes. Despite being readily preventable and treatable, malaria remains a massive global public health problem and it occurs in more than 100 countries and territories worldwide. About half of the world’s population is at risk, with large areas of Africa and South Asia, along with parts of Central and South America, the Caribbean, Southeast Asia, the Middle East and Oceania considered areas where malaria transmission occurs.

Global highlights

The latest WMR finds that, despite disruptions to prevention, diagnostic, and treatment services during the COVID-19 pandemic, along with other challenges (such as humanitarian crises, natural disasters, funding deficits, and global inflation, among others), countries around the world “have largely held the line against further setbacks to malaria control.” Around the world, there were an estimated 619,000 deaths due to malaria in 2021, which was about 6,000 fewer than in 2020 but still around 51,000 higher than in 2019 and prior to the onset of the COVID-19 pandemic. Furthermore, although the number of cases of malaria rose again in 2021, estimated to be about 247 million cases, the rise was at a slower pace than the previous year. (In 2020, there were 245 million cases, while 2019 saw 232 million cases.) Overall, between 2019 and 2021, an estimated additional 13.4 million cases and 63,000 deaths were attributed to disruptions associated with the COVID-19 pandemic(such as disruptions in diagnosis, treatment, or insecticide-treated mosquito net (ITN) distribution campaigns). Yet again, Africa, and Sub-Saharan Africa (SSA) more specifically, carries the greatest burden of malaria. Last year saw an estimated 234 million cases(95 percent of the global total) and 593,000 deaths (96 percent) in SSA, while the top 16 most malaria-affected countries in the world, in terms of cases, are all located in the region. Four African countries, Nigeria, the Democratic Republic of the Congo (DRC), Uganda, and Mozambique, accounted for nearly half of all cases globally, with four African countries also accounting for more than half of all malaria deaths globally (Nigeria, DRC, Niger, and Tanzania).

Eritrea

In Eritrea, malaria has been along standing challenge and the risk of malaria remains moderate to high within large swathes of the country. Forty-one of the country’s58 sub-zobas are categorized as malaria-endemic localities, with the Gash Barka, Debub, and Semenawi Keih Bahri regions accounting for greater than 90 percent of the national burden. (Gash Barka and Debub account for the vast majority of the national malaria burden.) Historically, malaria has been a formidable threat to several vulnerable population groups, such as pregnant women and children.(Young children are vulnerable as they have not developed immunity to malaria, and pregnant women are vulnerable as their immunity has been decreased by pregnancy.)

Since independence, and particularly following the establishment of the National Malaria Control Program in 1995, Eritrea has made major inroads against the disease. Through the combination of an array of control and prevention interventions, which has included the mass distribution of long-lasting insecticide-treated nets, indoor residual spraying, drainage and larval source management, effective case management and surveillance, and strong community mobilization, awareness, and reception, the national malaria burden has been significantly reduced.

Relying on both the WMR and local sources, between 1998 and 2016, malaria incidence in Eritrea dropped significantly, declining from 157 to 34 cases per 1,000 people. Following further reductions to 18 cases per 1,000 in 2018, there has been a slight increase in cases in recent years, to 30 cases per 1,000 in 2020. (Similarly, the WMR estimates that the recent rise has been reversed, with total cases in Eritrea in 2021 decreasing by about 54 percent compared to 2019 and 2020.) Shifting to malaria deaths, they too have fallen, dropping from 405 in 1998 to 23 in 2016 and 6in 2021 (an overall reduction of approximately 99 percent). Notably, in recent years, only a small percentage of all malaria cases in the country were in highly vulnerable populations, such as children under five years of age or pregnant women.

Notably, Eritrea’s progress over the years made it one of a small number of countries to achieve the United Nations Millennium Development Goals target related to malaria (Goal 6, which it meta head of the 2015 target date). In 2016, during the 26th Summit of the African Union (AU), it even received an award from the African Leaders Malaria Alliance in recognition of its “commitment, innovation, and progress in the fight against malaria.” (The African Leaders Malaria Alliance is a coalition of AU Heads of State and Government established to drive accountability and action for results against malaria and neglected tropical diseases, and to promote reproductive, maternal and child health.)

Looking ahead, despite a recent rise in cases in some areas of the country, Eritrea is steadily transitioning from pre-elimination toward elimination of malaria, with the long-term goal of ultimately eliminating and preventing the re-introduction of malaria by 2030. (The path to malaria-free status is characterized by four distinct programmatic phases: control, pre-elimination, elimination, and prevention of reintroduction. Subsequently, once a country has proven, beyond a reasonable doubt, that the chain of local malaria transmission by Anopheles mosquitoes has been interrupted nationwide for at least three consecutive years, it is then granted a certification of malaria-free status from the WHO.)

Encouragingly, entomology laboratories for research have been established in Elabered and Tesseney, helping in the identification of species and parasites, while efforts continue to ensure early diagnosis and treatment, as it prevents deaths and contributes to reducing transmission. Additionally, local reports indicate that Eritrea will develop a refined sub-national stratification map based on epidemiological data triangulated with appropriate metrics, namely entomological, ecological/demography, and interventions coverage data, to better disaggregate the malaria situation and inform targeting of interventions.

Something to keep an eye on

In addition to the potential threat sposed by mosquito evolution and adaptability, their growing resistance to insecticide-treated nets, and anti malarial drug resistance, another issue for consideration is climate change. Specifically, scientists have indicated that climate change could significantly impact the distribution and transmission of malaria. For instance, a rise in temperature could mean that malaria parasites develop faster, thus raising the potential for transmission and burden. With Eritrea, and the Horn of Africa region more broadly, at particular threat from a changing climate, this potential issue remains one to keep an eye on.

Source: Ministry of Information Eritrea